YEZTUGO HCP

YEZTUGO is a groundbreaking brand known for its innovative protection against HIV, featuring the first and only 6-month subcutaneous injectable solution, lenacapavir. This long-acting option is specifically designed for pre-exposure prophylaxis (PrEP) to significantly reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing 35 kg or more who are at elevated risk. The product has undergone rigorous clinical trials, making it the most inclusive in terms of age, gender, and race, and has been recognized as the Science 2024 Breakthrough of the Year for its unique ability to disrupt the HIV-1 life cycle.

YEZTUGO stands out with its twice-a-year dosing regimen, providing convenient office administration with minimal interruption. The brand places a strong emphasis on safety, advising individuals to confirm their HIV-negative status before initiating treatment. Moreover, YEZTUGO supports patients through various acquisition pathways and educational resources, ensuring comprehensive care that includes ongoing HIV screening and adherence strategies. With its combination of efficacy, safety, and patient-centered services, YEZTUGO is setting new standards in HIV prevention.